SearcharxivSearch

arXiv subjects

Mark Davies

Publications and source records attributed to Mark Davies.

3 recordsLinked to original sources

Bayesian Profile Regression using Variational Inference to Identify Clusters of Multiple Long-Term Conditions Conditioning on Mortality in Population-Scale Data

Multiple long-term conditions (MLTC) are increasingly observed in clinical practice globally. Clustering methods to group diseases into commonly co-occurring clusters have been of interest for further understanding of how MLTC group together and their associated impact on patient outcomes. However, such approaches require large, often population-scale datasets. Bayesian Profile Regression (BPR) is a statistical model that combines a Dirichlet Process Mixture model with a hierarchical regression model, in order to form clusters of items conditional on covariates and an outcome of interest. We developed a BPR model using full-rank Stochastic Variational Inference (SVI) for application in large-scale data. We assessed it's performance using simulation studies comparing fits using the No-U-turn (NUTS) sampler and full-rank SVI. We then fit a BPR model to find clusters of MLTC in a population-scale data held in the Secure Anonymised Information Linkage (SAIL) databank. We found results from full-rank SVI compared well with results from NUTS in a simulation study, and the improved fitting performance allowed for fitting models in population-scale datasets. There were 1,296,463 individuals in our electronic health record (EHR) cohort. The clustering model was conditioned on age at cohort entry, socioeconomic deprivation and sex with mortality as the outcome. We used the Elixhauser comorbidity index disease definitions, and found there were 33 disease clusters. We found that clusters featuring metastatic cancer and cardiovascular diseases, such as congestive heart failure, were most strongly associated with the probability of mortality. Our findings show that SVI can be a useful and accurate method for fitting Bayesian models, especially when the dataset size would make Monte Carlo methods prohibitively time consuming or impossible.

stat.AP

AI Agents in Drug Discovery

Artificial intelligence (AI) agents are emerging as transformative tools in drug discovery, with the ability to autonomously reason, act, and learn through complicated research workflows. Building on large language models (LLMs) coupled with perception, computation, action, and memory tools, these agentic AI systems could integrate diverse biomedical data, execute tasks, carry out experiments via robotic platforms, and iteratively refine hypotheses in closed loops. We provide a conceptual and technical overview of agentic AI architectures, ranging from ReAct and Reflection to Supervisor and Swarm systems, and illustrate their applications across key stages of drug discovery, including literature synthesis, toxicity prediction, automated protocol generation, small-molecule synthesis, drug repurposing, and end-to-end decision-making. To our knowledge, this represents the first comprehensive work to present real-world implementations and quantifiable impacts of agentic AI systems deployed in operational drug discovery settings. Early implementations demonstrate substantial gains in speed, reproducibility, and scalability, compressing workflows that once took months into hours while maintaining scientific traceability. We discuss the current challenges related to data heterogeneity, system reliability, privacy, and benchmarking, and outline future directions towards technology in support of science and translation.

cs.LG

Want Drugs? Use Python

We describe how Python can be leveraged to streamline the curation, modelling and dissemination of drug discovery data as well as the development of innovative, freely available tools for the related scientific community. We look at various examples, such as chemistry toolkits, machine-learning applications and web frameworks and show how Python can glue it all together to create efficient data science pipelines.

cs.OH